Journal Article

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

Amodio, N, Tassone, P, Anderson, K C, Hideshima, T, Tagliaferri, P, Gullà, A, Carrasco, R, Harada, T, Morelli, E, Fulciniti, M, Munshi, N C, Tai, Y-t, Bianchi, G, Qi, J, Kemal Samur, M

2018

Overview

Arginine methyltransferases critically regulate cellular homeostasis by modulating the functional outcome of their substrates. The protein arginine methyltransferase 5 (PRMT5) is an enzyme involved in growth and survival pathways promoting tumorigenesis. However, little is known about the biologic function of PRMT5 and its therapeutic potential in multiple myeloma (MM). In the present study, we identified and validated PRMT5 as a new therapeutic target in MM. PRMT5 is overexpressed in patient MM cells and associated with decreased progression-free survival and overall survival. Either genetic knockdown or pharmacological inhibition of PRMT5 with the inhibitor EPZ015666 significantly inhibited growth of both cell lines and patient MM cells. Furthermore, PRMT5 inhibition abrogated NF-κB signaling. Interestingly, mass spectrometry identified a tripartite motif-containing protein 21 TRIM21 as a new PRMT5-partner, and we delineated a TRIM21-dependent mechanism of NF-κB inhibition. Importantly, oral administration of EPZ015666 significantly decreased MM growth in a humanized murine model of MM. These data both demonstrate the oncogenic role and prognostic relevance of PRMT5 in MM pathogenesis, and provide the rationale for novel therapies targeting PRMT5 to improve patient outcome.

• Publisher: Nature Publishing Group
• Subject: Animal models / Arginine / Homeostasis / Inhibition / Mass spectrometry / Mass spectroscopy / Medical prognosis / Multiple myeloma / NF-κB protein / Oral administration / Pathogenesis / Pharmacology / Protein arginine methyltransferase / Proteins / Signaling / Substrates / Survival / Therapeutic applications / Tumorigenesis